Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
iRhythm Technologies is a digital healthcare company specializing in ambulatory cardiac monitoring through its proprietary Zio patch platform, which captures continuous ECG data for up to 14 days to detect arrhythmias. The company operates primarily in the U.S. market serving cardiologists, electrophysiologists, and primary care physicians with a subscription-based diagnostic service model. With 68.9% gross margins but negative operating margins, iRhythm is in a growth-investment phase focused on market penetration and expanding its AI-powered diagnostic algorithms.
iRhythm generates revenue through a service model where healthcare providers prescribe Zio patches for patients suspected of arrhythmias. The company bills insurers (Medicare, Medicaid, commercial payers) per monitoring episode at reimbursement rates typically ranging $300-500 per patch depending on wear duration and analysis complexity. Competitive advantages include proprietary AI algorithms (ZEUS system) with superior arrhythmia detection rates versus traditional Holter monitors, extensive clinical validation across 500+ peer-reviewed publications, and established relationships with major cardiology practices. The company benefits from recurring demand as cardiac monitoring is episodic rather than one-time, and switching costs are moderate due to physician familiarity and EMR integration.
Quarterly Zio patch volume growth and average selling price trends - unit economics drive revenue trajectory
Medicare and commercial reimbursement rate decisions - CMS coverage policies and private payer contract renewals significantly impact revenue per test
Operating margin progression toward breakeven - investors closely track path to profitability given current -19.5% operating margins
Competitive threats from Abbott, Medtronic, and BioTelemetry (Philips) in ambulatory cardiac monitoring space
Clinical study results validating Zio superiority and expanding addressable indications beyond arrhythmia detection
Reimbursement compression risk - CMS and commercial payors face budget pressures and may reduce per-test reimbursement rates, which have historically declined 5-10% in certain categories as technologies mature and competition increases
Technological disruption from smartwatch-based cardiac monitoring - Apple Watch, Samsung, and Fitbit ECG capabilities could commoditize basic arrhythmia detection, though clinical-grade 14-day continuous monitoring remains differentiated
Regulatory pathway changes - FDA reclassification or new clinical evidence requirements for ambulatory cardiac monitors could increase compliance costs or delay product iterations
Market share erosion from Abbott (CardioMEMS, insertable cardiac monitors) and Medtronic expanding into extended wear monitoring with established cardiology relationships and broader device portfolios
BioTelemetry integration into Philips creating a well-capitalized competitor with global distribution and hospital system contracts that bundle monitoring with other diagnostic equipment
Pricing pressure as multiple vendors compete for cardiology practice contracts, potentially forcing volume discounts or value-based arrangements that reduce per-patch economics
High leverage at 6.01x debt/equity with convertible notes requiring refinancing or conversion - estimated $400M+ debt outstanding creates refinancing risk if equity price remains depressed or credit markets tighten
Negative operating cash flow and -19.5% operating margins mean the company is burning cash and may require equity raises that dilute existing shareholders, particularly problematic given recent 12.3% three-month stock decline
Working capital pressure from accounts receivable concentration in healthcare payors with extended collection cycles, requiring careful liquidity management
low - Healthcare diagnostics demonstrate defensive characteristics as cardiac monitoring is medically necessary rather than discretionary. However, moderate sensitivity exists through two channels: (1) employment-linked commercial insurance coverage affects patient volumes, with unemployment spikes reducing insured population, and (2) hospital and physician practice budgets can tighten during recessions, potentially delaying adoption of premium-priced monitoring solutions. Overall demand remains relatively stable through economic cycles as arrhythmia prevalence is age-driven rather than economically sensitive.
Rising interest rates create moderate headwinds through multiple channels. First, iRhythm's 6.01x debt/equity ratio means higher refinancing costs on the company's convertible debt (estimated $400M+ outstanding), directly impacting interest expense. Second, as a pre-profitable growth company trading at 6.7x sales, valuation multiples compress when risk-free rates rise as investors demand higher equity risk premiums. Third, higher rates can pressure healthcare system capital budgets, potentially slowing adoption of new diagnostic technologies. The company's negative free cash flow (-0.6% FCF yield) means it may need external financing, making credit conditions material.
Moderate credit exposure exists through healthcare reimbursement cycles and payor mix. Approximately 40-50% of revenue is estimated to come from government payors (Medicare/Medicaid) with 90-120 day collection cycles, while commercial insurers represent 50-60% with varying payment terms. Tightening credit conditions could stress hospital and physician practice cash flows, potentially extending days sales outstanding. The company's 4.63x current ratio provides liquidity cushion, but sustained cash burn requires access to capital markets where credit spreads directly impact financing costs and availability.
growth - The stock attracts growth investors focused on healthcare innovation and market share expansion in a large addressable market (estimated $5B+ U.S. cardiac monitoring market). The 20.1% revenue growth, negative profitability, and 6.7x price/sales multiple indicate investors are paying for future earnings potential rather than current cash generation. The 30.6% one-year return despite recent volatility suggests momentum investors also participate during positive clinical or reimbursement catalysts. Not suitable for value or income investors given negative earnings, no dividend, and premium valuation.
high - Medical device stocks in growth phase with binary reimbursement and regulatory catalysts exhibit elevated volatility. The recent -12.3% three-month decline followed by 30.6% one-year gain demonstrates significant price swings. As a $4.7B market cap company with negative profitability, the stock is sensitive to quarterly earnings surprises, reimbursement policy changes, and competitive announcements. Institutional ownership concentration and relatively modest trading volumes can amplify price movements on news flow.